2023
Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis
Liverman R, Serluco A, Nance G, George R, Rodriguez D, Deshpande S, Mao C, Garro R, Yildirim I. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis. Pediatric Transplantation 2023, 27: e14493. PMID: 36945819, DOI: 10.1111/petr.14493.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsPediatric solid organ transplant recipientsCytomegalovirus DNAemiaValganciclovir prophylaxisDose reductionRisk factorsTransplant recipientsImpact of dose adjustmentsRisk factors associated with failureFactors associated with failureOrgan transplant recipientsHeart transplant recipientsIndependent risk factorRetrospective cohort studyAssociated with morbidityCMV DNAemiaCytomegalovirus eventsValganciclovir dosingImmunosuppressive therapyDose adjustmentYounger age groupsDNAemiaValganciclovirRisk stratificationAdverse events
2008
Cytomegalovirus hepatitis and ganciclovir treatment in immunocompetent children.
Tezer H, Seçmeer G, Kara A, Ceyhan M, Cengiz AB, Devrim I, Us D, Yüce A, Gürakan F, Yildirim I, Ozen H, Saltik-Temizel IN. Cytomegalovirus hepatitis and ganciclovir treatment in immunocompetent children. The Turkish Journal Of Pediatrics 2008, 50: 228-34. PMID: 18773667.Peer-Reviewed Original ResearchConceptsBiliary atresiaGanciclovir treatmentCauses of hepatitisCongenital CMV infectionExtrahepatic biliary atresiaSigns of infectionCMV hepatitisCholestatic hepatitisCMV infectionCytomegalovirus infectionImmunocompetent childrenStudy groupHepatitisPatientsGroup IIDemographic featuresGroup IInborn errorsInfectionAtresiaChildrenTreatmentGroupGenetic diseasesCMV